ESMO 2024 – degraders disappoint again
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
A Prelude to a Lilly duel
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
Prelude’s SMARCA2 project and C4’s BRAF hopeful look lacklustre.
The leading proponents of selective SMARCA2 inhibition are taking their oral projects into clinical trials.
